58 related articles for article (PubMed ID: 11448931)
1. The impact of p53 status on cellular sensitivity to antifolate drugs.
Lu X; Errington J; Curtin NJ; Lunec J; Newell DR
Clin Cancer Res; 2001 Jul; 7(7):2114-23. PubMed ID: 11448931
[TBL] [Abstract][Full Text] [Related]
2. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
3. Expression of P53, P21 in human lung adenocarcinoma A549 cell strains under hypoxia conditions and the effect of TSA on their expression.
Huang H; Zhang Z; Xu Y; Shao J
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(4):359-61. PubMed ID: 15015635
[TBL] [Abstract][Full Text] [Related]
4. A human cell line from a pleural effusion derived from a breast carcinoma.
Soule HD; Vazguez J; Long A; Albert S; Brennan M
J Natl Cancer Inst; 1973 Nov; 51(5):1409-16. PubMed ID: 4357757
[No Abstract] [Full Text] [Related]
5. Galactosylceramide Upregulates the Expression of the
Suchanski J; Reza S; Urbaniak A; Woldanska W; Kocbach B; Ugorski M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254878
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-874 targets phosphomevalonate kinase and inhibits cancer cell growth via the mevalonate pathway.
Aersilan A; Hashimoto N; Yamagata K; Yokoyama M; Nakayama A; Shi X; Nagano H; Sakuma I; Nohata N; Kinoshita T; Seki N; Rahmutulla B; Kaneda A; Zhahara SN; Gong Y; Nishimura M; Kawauchi S; Kawakami E; Tanaka T
Sci Rep; 2022 Nov; 12(1):18443. PubMed ID: 36323841
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines.
Thongchot S; Jamjuntra P; Prasopsiri J; Thuwajit P; Sawasdee N; Poungvarin N; Warnnissorn M; Sa-Nguanraksa D; O-Charoenrat P; Yenchitsomanus PT; Thuwajit C
Oncol Rep; 2021 Dec; 46(6):. PubMed ID: 34651665
[TBL] [Abstract][Full Text] [Related]
8. Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.
Yao JY; Xu S; Sun YN; Xu Y; Guo QL; Wei LB
Acta Pharmacol Sin; 2022 Apr; 43(4):1033-1045. PubMed ID: 34188177
[TBL] [Abstract][Full Text] [Related]
9. Genomic Characterization of Cisplatin Response Uncovers Priming of Cisplatin-Induced Genes in a Resistant Cell Line.
Golan Berman H; Chauhan P; Shalev S; Hassanain H; Parnas A; Adar S
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071702
[TBL] [Abstract][Full Text] [Related]
10. Expression of Dopamine D
Wysokiński A; Kozłowska E; Szczepocka E; Łucka A; Agier J; Brzezińska-Błaszczyk E; Sobierajska K
Front Psychiatry; 2021; 12():645081. PubMed ID: 33776821
[No Abstract] [Full Text] [Related]
11. Polyphenol Extract from Evening Primrose (
Chmielewska-Kassassir M; Sobierajska K; Ciszewski WM; Bukowiecka-Matusiak M; Szczesna D; Burzynska-Pedziwiatr I; Wiczkowski W; Wagner W; Wozniak LA
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228230
[TBL] [Abstract][Full Text] [Related]
12. Protoflavone-Chalcone Hybrids Exhibit Enhanced Antitumor Action through Modulating Redox Balance, Depolarizing the Mitochondrial Membrane, and Inhibiting ATR-Dependent Signaling.
Latif AD; Jernei T; Podolski-Renić A; Kuo CY; Vágvölgyi M; Girst G; Zupkó I; Develi S; Ulukaya E; Wang HC; Pešić M; Csámpai A; Hunyadi A
Antioxidants (Basel); 2020 Jun; 9(6):. PubMed ID: 32545536
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action.
Spaczyńska E; Mrozek-Wilczkiewicz A; Malarz K; Kos J; Gonec T; Oravec M; Gawecki R; Bak A; Dohanosova J; Kapustikova I; Liptaj T; Jampilek J; Musiol R
Sci Rep; 2019 Apr; 9(1):6387. PubMed ID: 31011161
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
Fabi F; Adam P; Vincent K; Demontigny F; Parent S; Joncas FH; Asselin E
Cell Commun Signal; 2018 Jul; 16(1):39. PubMed ID: 29973205
[TBL] [Abstract][Full Text] [Related]
15. Regulatory role of resveratrol, a microRNA-controlling compound, in
Otsuka K; Yamamoto Y; Ochiya T
Oncotarget; 2018 May; 9(37):24718-24730. PubMed ID: 29872500
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.
Zanjirband M; Curtin N; Edmondson RJ; Lunec J
Oncotarget; 2017 Sep; 8(41):69779-69796. PubMed ID: 29050241
[TBL] [Abstract][Full Text] [Related]
17. UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway.
Luo Y; He J; Yang C; Orange M; Ren X; Blair N; Tan T; Yang JM; Zhu H
J Cell Biochem; 2018 Jan; 119(1):691-700. PubMed ID: 28636190
[TBL] [Abstract][Full Text] [Related]
18. Lack of Casein Kinase 1 Delta Promotes Genomic Instability - The Accumulation of DNA Damage and Down-Regulation of Checkpoint Kinase 1.
Greer YE; Gao B; Yang Y; Nussenzweig A; Rubin JS
PLoS One; 2017; 12(1):e0170903. PubMed ID: 28125685
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
20. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.
Xie X; Lozano G; Siddik ZH
Oncogene; 2016 Sep; 35(36):4798-806. PubMed ID: 26876197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
